SentiAR brought on a new investor and closed a $5.1 million Series A round. The company has an FDA approved mixed reality, holographic ‘guidance system’ for cardiac surgery and other interventional procedures. The St. Louis-based startup has raised a total of $15.1 million from investors that include BioGenerator, Cultivation Capital, Neue Fund, Vcapital, QRM Capital, Keiretsu Forum and the newly joined TechWald Holding.
Berk Tas, SentiAR CEO
“It gives us the necessary means to hire some talent to build-out some infrastructure and continue with our partnerships – clinical and strategic,” SentiAR CEO Berk Tas told the 4thESt8. “Our company is focused on interventional procedures and our products. So when you talk about SentiAR’s product, yeah, our product name is CommandEP, and that product is focused on cardiac electrophysiology… we don’t do anything with open surgery. You know, that’s why (it’s) interventional.”
The company’s system presents a 3D holographic image of the patient’s hart, showing the real-time positions of catheters used for the procedure via a wearable headset.
In 2018 the startup landed Phase I and Phase II SBIR grants from the National Institutes of Health, Department of Health and Human Services totaling $2,221,372 for the commercialization of technologies developed at Washington University, St. Louis by Dr. Jennifer Silva MD and Dr. Jonathan Silva Ph.D. The company currently has seven full time employees, all technical.
